India’s largest drugmaker, Sun Pharmaceutical Industries, has announced the acquisition of Mumbai-based Innovcare Lifesciences in an all-cash deal valued at ₹271.2 crore. The move is aimed at strengthening Sun Pharma’s presence in the fast-growing nutraceutical and cosmeceutical segments while expanding its overall healthcare portfolio.
Under the agreement, Sun Pharma will acquire 100% ownership of Innovcare Lifesciences, a company engaged in the marketing, distribution and sale of pharmaceutical, nutraceutical and cosmeceutical products. The transaction is expected to be completed on or before July 31, 2026.
The acquisition reflects Sun Pharma’s strategy of broadening its offerings beyond traditional prescription medicines. With increasing consumer focus on preventive healthcare, nutrition and wellness products, nutraceuticals have emerged as one of the fastest-growing segments in the healthcare industry. Innovcare’s portfolio is expected to help Sun Pharma deepen its presence in these categories.
Founded in 2014, Innovcare has built a business around health supplements, pharmaceutical products and personal care solutions. The company reported revenue of ₹94.06 crore in FY26, continuing a steady growth trend over the past three years. Its established distribution network and product portfolio were key factors behind the acquisition.
Sun Pharma described the purchase as a strategic investment designed to strengthen its product basket and enhance long-term growth opportunities. Industry analysts believe the deal will allow the pharmaceutical major to tap into rising demand for wellness and lifestyle-focused healthcare products, complementing its strong position in the prescription drug market.
The acquisition also highlights Sun Pharma’s continued focus on expansion through targeted investments. In recent years, the company has pursued several strategic initiatives to diversify its business and reinforce its leadership position in the healthcare sector.
Also Read: Aavas Financiers shares dips 3% after NHB flags concerns